Two recent
developments involving the California Institute for Regenerative Medicine (CIRM) again serve to underscore the reality that adult and other non-embryonic avenues of stem cell research are advancing at a far more dramatic pace
toward providing actual
therapeutic benefits for patients than is human embryonic stem cell research (hESCR).
The aim of the division is to develop translational research programmes and clinical research, but any significant progress
toward the cure of cancer can only be based on an improved understanding of its pathogenesis, which, in turn, will lead to the
development of improved diagnostics and more rationale
therapeutic interventions.